Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
94 hedge funds and large institutions have $636M invested in Ra Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 39 increasing their positions, 14 reducing their positions, and 8 closing their positions.
313% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 8
179% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 14
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
45% more capital invested
Capital invested by funds: $438M → $636M (+$198M)
36% more funds holding
Funds holding: 69 → 94 (+25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$37.3M |
| 2 |
DM
Deerfield Management
New York
|
+$17.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$15.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.9M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$26.3M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.07M |
| 3 |
JP Morgan Chase
New York
|
-$1.18M |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$1.03M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$886K |
RARX Hedge Fund Activity: Q4 2018 in Review
94 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q4 2018, worth a combined $636M — up 45% from $438M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new RARX positions and 8 closed out — a net gain of 25 holders — while 39 added to existing stakes and 14 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $37.3M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $26.3M sold.
- 94 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q4 2018, up from 69 in Q3 2018.
- Funds reported $636M of Ra Pharmaceuticals, Inc. Common Stock stock for Q4 2018, up 45% quarter-over-quarter.
- 33 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 8 closed out, a net change of +25 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Wellington Management Group, an estimated $37.3M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Consonance Capital Management, an estimated $26.3M sold.
Based on aggregated 13F filings for Q4 2018.